# Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

> **NCT00414310** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 153 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Valproic Acid

## Key facts

- **NCT ID:** NCT00414310
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2019-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414310, "Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00414310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*